MaxCyte (LON:MXCT) Trading 3.4% Higher – What’s Next?

MaxCyte, Inc. (LON:MXCT) shares were up 3.4% during mid-day trading on Thursday . The company traded as high as GBX 340 ($4.29) and last traded at GBX 335 ($4.23). Approximately 12,456 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 30,823 shares. The stock had previously closed at GBX 324 ($4.09).

MaxCyte Price Performance

The company has a 50-day moving average of GBX 283.88 and a 200 day moving average of GBX 315.26. The company has a debt-to-equity ratio of 8.37, a quick ratio of 14.38 and a current ratio of 14.31. The firm has a market cap of £351.00 million, a P/E ratio of -1,292.31 and a beta of 1.13.

Insider Buying and Selling at MaxCyte

In related news, insider Stan Erck sold 47,689 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of GBX 388 ($4.90), for a total transaction of £185,033.32 ($233,539.47). Company insiders own 1.45% of the company’s stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.